A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of D4064A Administered Intravenously to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer After a Platinum-Containing Regimen.
Phase of Trial: Phase I
Latest Information Update: 25 Nov 2014
At a glance
- Drugs RG 7882 (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors Genentech
- 01 Sep 2014 New source identified and integrated (Memorial Sloan-Kettering Cancer Center: 08-098).
- 06 Nov 2008 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 07 Oct 2008 New trial record.